Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. This milestone advances the company's chemistry, manufacturing, and controls (CMC) strategy as it progresses toward IND-enabling studies and planning for first-in-human clinical evaluation.
The program will focus on optimizing synthetic processes, improving yield and reproducibility, and scaling production of key intermediates required for downstream manufacturing and formulation. The work will be conducted in collaboration with Dalton Pharma Services to establish a robust, scalable manufacturing process capable of supporting continued preclinical development, regulatory readiness, and future clinical supply requirements.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco has secured an exclusive worldwide license to patented technology that targets solid tumors. For more information, visit https://oncoinnovations.com/.
This development is important because it moves ONC010 closer to clinical trials, potentially offering a new treatment option for patients with solid tumors. The advancement of the manufacturing process is a critical step in ensuring that the drug can be produced at scale with consistent quality, which is essential for regulatory approval and eventual commercialization.
